ライフサイエンスコーパス: furosemide

1 tions, and is inhibited by the loop diuretic furosemide.

2 R2* was elevated at baseline, but fell after furosemide.

3 low levels of R2* that did not change after furosemide.

4 ained before and after the administration of furosemide.

5 all benefit of administering both saline and furosemide.

6 l body irradiation unless NaCl is lowered by furosemide.

7 el is decreased by injection of the diuretic furosemide.

8 nd isoproterenol responsiveness depressed by furosemide.

9 icted and were maintained on stable doses of furosemide.

10 was not further impaired by papillectomy or furosemide.

11 1 antagonist, and also by 100 microM luminal furosemide.

12 oncentrate and dilute urine, and response to furosemide.

13 of INDO, followed immediately by 1 mg/kg of furosemide.

14 enally metabolized loop diuretic rather than furosemide.

15 id to the mitochondria was also prevented by furosemide.

16 se to desmopressin and an intact response to furosemide.

17 accumulation in the cytosol was prevented by furosemide.

18 er albumin regimen increased the response to furosemide.

19 fter the acute administration of intravenous furosemide.

20 n in NaCl concentration and by bumetanide or furosemide.

21 athways were activated by the diuretic drug, furosemide.

22 vehicle (sterile isotonic saline) instead of furosemide.

23 ys, 12 patients received placebo, BG9719 and furosemide.

24 iving BG9719 and 374 +/- 231 after receiving furosemide.

25 status were obtained prior to administering furosemide.

26 not predictive of urinary output response to furosemide.

27 ut doubled in 20 patients (67%) following IV furosemide.

28 nyl, metoprolol, lorazepam, hydralazine, and furosemide.

29 in rats by treatment with the diuretic drug, furosemide.

30 l derivative of the arylsulfonamide compound furosemide.

31 magnetic resonance imaging before and after furosemide.

32 tenuation was lower in patients who received furosemide (-0.1 HU) compared with those who did not (6.

33 Infants received intravenous furosemide (1 mg/kg every 6 hours) or a standardized PD

34 Thirty-two Yorkshire pigs were randomized to furosemide (1 mg/kg intramuscularly daily, mean 16.1 +/-

35 a baseline clearance, 1 group (F+V) received furosemide (1 mg/kg per hour) plus saline for 90 minutes

36 which involves intravenous administration of furosemide (1.0 or 1.5 mg/kg), can predict the developme

37 P < 0.02) and correspondingly lower tmax for furosemide (1.8 +/- 0.3 vs 4.2 +/- 1.2 hours, P = 0.006)

38 GABA-activated currents were insensitive to furosemide (10-1000 microM) in all NTS neurons tested.

39 in weight (-2.19 vs. -1.58 kg), intravenous furosemide (125 vs. 107 mg), discontinuation of the infu

40 20% mannitol (2.5 g/kg bolus every 6 hrs) or furosemide (2.5 mg/kg bolus every 6 hrs).

41 four treatments intravenously: (1) 40 mg of furosemide, (2) 25 g of albumin, (3) 40 mg of furosemide

42 eriment 1, animals treated with the diuretic furosemide (20 mg/kg) when denied access to saline exhib

43 ague-Dawley rats received vehicle (group 1), furosemide (22 mg/100 g body wt per d) (group 2), or fur

44 seen less commonly in patients who received furosemide (27 of 111, 24%) than in those who did not re

45 n drinking water), four weeks of ALDO/salt + furosemide (40 mg/kg in prepared food), and four weeks o

46 L/hr for 2 hr) or diuretic treatment (n = 8, furosemide, 40 mg every 30 min, total 160 mg) and compar

47 Baseline and furosemide (99m)Tc-MAG3 imaging examinations in 50 patie

48 mitochondria, an event that was inhibited by furosemide, a chloride channel inhibitor.

49 Furosemide, a loop diuretic, is commonly used in patient

50 ained before and after the administration of furosemide, a masked expert determined whether each kidn

51 addition, sIPSC frequency was attenuated by furosemide, a selective antagonist of alpha6 subunits.

52 Inhibition of TGF (by furosemide) abolished the l-NAME effect on the myogenic

53 We tested the hypothesis that furosemide accelerates the progression of left ventricul

54 re automatically extracted from baseline and furosemide acquisitions and forwarded to the expert syst

55 Furosemide activates the renin-angiotensin-aldosterone s

56 acute decompensated heart failure to receive furosemide administered intravenously by means of either

57 edullary hyperattenuation and the absence of furosemide administration (P = .002), younger age (P < .

58 yltriglycine ((99m)Tc-MAG3) scan followed by furosemide administration and a separate 20-min acquisit

59 In this experiment, furosemide administration increased the number of Fos-po

60 Furosemide administration prior to unenhanced CT is asso

61 or day of discharge if earlier, intravenous furosemide administration tended to be lower in the KW-3

62 nd the half-life of renal signal decay after furosemide administration was derived and compared with

63 in treatment between arms was predominantly furosemide administration, which was not associated with

64 odium excretion was 104 +/- 78 mEq following furosemide administration.

65 volunteers before and after water loading or furosemide administration.

66 However, in mice treated acutely with furosemide, administration of PDSinh-C01 produced a 30%

67 eritance with some cloned progeny exhibiting furosemide affinities outside the range of parental valu

68 ing of the 3D7A clone also exhibited altered furosemide affinities, implicating changes in one or mor

69 intravenous furosemide (n = 26), or 10 mg of furosemide alone (n = 26).

70 creted: 49 +/- 15 mg versus 54 +/- 12 mg for furosemide alone and furosemide plus sulfisoxazole, resp

71 Furosemide alone caused a decline in GFR.

72 Although administration of furosemide alone caused a large diuresis, addition of BG

73 Sodium excretion (mean +/- SD) from furosemide alone was 239 +/- 90 versus 240 +/- 115 mEq/8

74 ography may be supplemented with intravenous furosemide alone.

75 .01), a reduced pharmacodynamics response to furosemide also became important when creatinine clearan

76 Wild-type mice treated with furosemide, an inhibitor of NaK2Cl cotransporters, have

77 In the presence of furosemide, an inhibitor of the Na,K,Cl-cotransporter, N

78 for warfarin, 83.3% for ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of a l

79 f albumin premixed ex vivo, and (4) 40 mg of furosemide and 25 g of albumin infused simultaneously in

80 urosemide, (2) 25 g of albumin, (3) 40 mg of furosemide and 25 g of albumin premixed ex vivo, and (4)

81 ts of adenosine blockade in humans receiving furosemide and ACE inhibitors is unknown.

82 In the BNP-driven group, furosemide and acetazolamide were given more often and i

83 orter is dominated by loop diuretics such as furosemide and bumetanide, molecules used in clinical me

84 e Pfizer drug library, including ingliforib, furosemide and celecoxib, we successfully prepared stabl

85 1Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P < 0.0001).

86 Furosemide and chlorthiazide are protective for unprovok

87 did not exhibit the natriuretic response to furosemide and exhibited a severely blunted response to

88 After administering single doses of furosemide and famciclovir (metabolized to penciclovir),

89 accompanies aldosteronism is aggravated with furosemide and is attenuated by spironolactone.

90 ntial in vivo by an intravenous injection of furosemide and measured the vibrations of different laye

91 in the prediction of the kidney clearance of furosemide and penciclovir.

92 Four case studies on warfarin, ibuprofen, furosemide and sertraline implied that our method was ab

93 Natriuresis is effectively induced by both furosemide and the adenosine A1 antagonist BG9719 in pat

94 was reduced (p < 0.05) at week 4 ALDO/salt + furosemide and was accompanied by hypokalemia (<3.4 mmol

95 g 48 hr of sodium depletion with a diuretic (furosemide) and a sodium deficient diet, rats displayed

96 ffect of Na(+)-influx inhibitors ranolazine, furosemide, and amiloride was evaluated.

97 ospital and treated with methylprednisolone, furosemide, and C1 esterase inhibitor.

98 micals (bezafibrate, climbazole, diclofenac, furosemide, and hydrochlorothiazide), the measured persi

99 in DGCs were sensitive to allopregnanolone, furosemide, and loreclezole and insensitive to diazepam

100 e current and noise, were sensitive to Zn2+, furosemide, and loreclezole; they were insensitive to di

101 ined a greater urine output, and 3) received furosemide; and slower in those with high blood concentr

102 osterone levels were significantly higher in furosemide animals (43.0 +/- 11.8 ng/dl vs. 17.6 +/- 4.5

103 days in placebo versus 21.4 +/- 3.2 days for furosemide animals; p = 0.038, log-rank test).

104 chlear potential (EP) is reduced by means of furosemide applied chronically to one cochlea of a young

105 liable predictor of the urinary output after furosemide (area under the receiver-operating-characteri

106 e furylated fluorophore dansyl and the drugs furosemide as well as furylated doxorubicin, by ultrasou

107 However, furosemide-associated diuresis was reduced only in male,

108 Three patients were given furosemide at 30 min after the radiopharmaceutical and w

109 ons of 10 mCi (370 MBq) 99mTc-MAG3 and 40 mg furosemide (at zero time, or F0).

110 In addition, luminal furosemide attenuated the [NaCl]L-dependent changes in i

111 system was evaluated in 95 randomly selected furosemide-augmented patient studies (185 kidneys) obtai

112 Using furosemide (BCS class IV compound) as a model compound,

113 In addition, 20 patients received 20 mg of furosemide before late scans.

114 Albumin with furosemide benefits lung physiology in hypoproteinemic p

115 AVP neurons was reversed by bumetanide, and furosemide blocked AVP release, both in vivo and in hypo

116 ample, GABAA receptor antagonists, including furosemide, blocked the spontaneous current.

117 modest effects on serum pharmacokinetics of furosemide but had no effect on either the time course o

118 atory markers, and medullary R2* response to furosemide, but directly with GFR response to acetylchol

119 ed (p < 0.05) with ALDO/salt and ALDO/salt + furosemide, but not with spironolactone co-treatment.

120 SND formulation increased C(max) and AUC of furosemide by 36.6 and 43.2 fold respectively, relative

121 formulation enhanced the absorptive flux of furosemide by more than 3-fold.

122 that mimics the effects of the loop diuretic furosemide, ClC-Kb/K2 is assumed to have a critical role

123 The kidney furosemide clearance correlated with iGFR (r=0.84) and t

124 or (MPE) between iGFR-predicted and measured furosemide clearance was 30.0%.

125 and 970 +/- 137 microg/24 h, respectively); furosemide co-treatment further increased (p < 0.05) uri

126 creatinine clearance, hourly plasma/urinary furosemide concentrations, and hourly urinary output wer

127 d large effects on binding of bumetanide and furosemide, consistent with the hypothesis that loop diu

128 essive saline hydration and varying doses of furosemide continue to be the standard of care for emerg

129 metabolic improvements were not affected by furosemide cotreatment.

130 ne, but these changes were not attenuated by furosemide cotreatment.

131 of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented

132 Furosemide-depleted rats that were allowed to drink 0.3

133 l medium reversibly inhibited transport, but furosemide did not.

134 ded mycophenolate, cyclosporine, prednisone, furosemide, diltiazem, aspirin, simvastatin, an angioten

135 ants (mean age, 69.8 years; 73.9% male; mean furosemide dose, 49.6+/-31.3 mg/d; mean HbA1c, 7.9+/-3.8

136 A portion of the furosemide effect can be prevented by blockade of minera

137 Furthermore, post-STEP and furosemide effects interacted occlusively, both on E(GAB

138 Here, we identified stable differences in furosemide efficacy against PSAC activity induced by HB3

139 Eplerenone treatment led to a mean furosemide equivalent dose reduction of -2.2 mg/day (-2.

140 Patients with higher furosemide equivalent doses had a worse clinical status.

141 tics other than furosemide were converted to furosemide equivalent doses.

142 Loop diuretic dose (furosemide equivalent) was 80 (40, 140) mg with both nes

143 95% CI: 0.51 to 2.17), daily loop diuretic, furosemide equivalents >240 mg (HR: 1.49, 95% CI: 0.68 t

144 (interquartile range, 40-270) mg intravenous furosemide equivalents increased FELi by 12.6%+/-10.8% (

145 pilot: stable outpatients receiving >/=80 mg furosemide equivalents were studied before and after 3 d

146 s the net fluid output produced per 40 mg of furosemide equivalents, then dichotomized into high vers

147 as calculated as net fluid balance per total furosemide equivalents.

148 Furosemide exaggerates these losses, whereas its combina

149 rongly associated with the amount of urinary furosemide excreted and was the only reliable predictor

150 reover, the relationship between the urinary furosemide excretion rate and the sodium excretion rate

151 ry sodium excretion and relating the urinary furosemide excretion rate to the sodium excretion rate.

152 pharmaceutical was administered 15 min after furosemide (F-15), whereas, in the second cohort of 29 p

153 cv infusions, rats were sodium depleted with furosemide, followed by the angiotensin-converting enzym

154 We also tested chlorthiazide and furosemide for seizure protection in animal models of ep

155 erefore, the coadministration of albumin and furosemide for the treatment of cirrhosis, and likely ot

156 etermine whether infants randomized to PD vs furosemide for the treatment of oliguria have a higher i

157 at PVP K12 and SDS were able to increase the furosemide free fraction available for oral absorption.

158 Furosemide (frusemide), which blocks only GABA(A),(fast)

159 he renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosteron

160 their binding competitors, ibuprofen (IBU), furosemide (FUR) and tryptophan (TRP) were studied in ur

161 AJ balloons received a combined treatment of furosemide (Furo; 10 mg (kg bw)(-1)) plus a low dose of

162 ter and sodium by injections of the diuretic furosemide (Furo; 10 mg/kg, bw) and given a low dose of

163 and to what extent, with sulfamethazine and furosemide, giving rise to possible allergic or hypersen

164 ences in mortality (3 patients [9.4%] in the furosemide group vs 1 patient [3.1%] in the PD group) or

165 The furosemide group was 3 times more likely to have 10% flu

166 No difference was found between the PD and furosemide groups in the incidence of negative fluid bal

167 ine output </=125 ml/h following intravenous furosemide >/=40 mg).

168 and were receiving a continuous infusion of furosemide (> or =6 mg/kg/day).

169 Tachycardic pigs given furosemide had significant acceleration of both contract

170 When BG9719 was added to furosemide, however, creatinine clearance remained at ba

171 Chronic treatment with either enalapril, furosemide, hydralazine, or losartan were all effective

172 oth pharmacokinetics and pharmacodynamics of furosemide in acute kidney injury, and was the only reli

173 predictor of the urinary output response to furosemide in acute kidney injury.

174 e determinants of urinary output response to furosemide in acute kidney injury; specifically, whether

175 in failed to enhance the diuretic effects of furosemide in cirrhotic patients with ascites.

176 beneficial cardiorenal actions when added to furosemide in experimental heart failure.

177 hat aminophylline is an effective adjunct to furosemide in increasing diuresis in critically ill chil

178 n and a significantly attenuated response to furosemide in isolated TALH segments.

179 The use of furosemide in the management of hypercalcemia should no

180 ver, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yi

181 Cotreatment with the diuretic furosemide in wild-type mice attenuated rosiglitazone-in

182 In mice treated long term with furosemide, in which renal pendrin is upregulated, PDSin

183 used a large diuresis, addition of BG9719 to furosemide increased diuresis, which was significant at

184 nts such as aminophylline, ascorbic acid, or furosemide increased or decreased endogenous wound elect

185 In these same patients, furosemide increased urine output at the expense of decr

186 Traditional diuretics such as furosemide induce substantial neurohormonal activation,

187 In the accompanying paper, furosemide-induced activation in the NTS and caudal thor

188 It is possible that the furosemide-induced activation in the SON and PVN is not

189 The furosemide-induced increase in urinary PGE(2) excretion

190 eriments lend support to our hypothesis that furosemide-induced neuronal activation in the thoracic s

191 ately when the patient was upright and after furosemide-induced volume depletion.

192 by a lumen-negative potential in response to furosemide infusion is abolished.

193 Moreover, furosemide-inhibitable transepithelial voltage is increa

194 In the second experiment, furosemide injection was preceded by treatment with a hi

195 After furosemide injection, the vibrations of the basilar memb

196 icacy of hypertonic saline was equivalent to furosemide (ipsilateral, 82.09 +/- 0.50%; contralateral,

197 CK1-/- mice and acutely in normal mice given furosemide is associated with lower NTE mRNA and protein

198 However, the widely used KCC2 inhibitor furosemide is nonselective with antiseizure efficacy in

199 s with normal nephrograms, administration of furosemide led to a 20% decrease in medullary R2* (P < 0

200 In the case of the organic anion, furosemide, loss of renal secretion in the knock-out res

201 no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline.

202 AG3 scintigraphy with zero time injection of furosemide (MAG3-F0) was observed to display focal paren

203 permeability, and high first-pass effect of furosemide may also have produced the effect that small

204 otensin II type 1 receptor ligand, preserved furosemide-mediated natriuresis and diuresis, while redu

205 n] mum(2)/msec, P = .0059; or 1.86 +/- 0.07 [furosemide] mum(2)/msec, P = .0094).

206 mL of normal saline and 10 mg of intravenous furosemide (n = 26), or 10 mg of furosemide alone (n = 2

207 C mRNA demonstrated no significant effect of furosemide (NCC/glyceraldehyde-3-phosphate dehydrogenase

208 BG9719 on 1 day and the same medication plus furosemide on a separate day.

209 ponse (defined as weight change per 40 mg of furosemide on day 4 after admission) and hemoconcentrati

210 dition, the effects of a therapeutic dose of furosemide on glomerular filtration rate (GFR) and renal

211 Furosemide only delayed full-length Bid depletion and tB

212 Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal bloc

213 ig ears deafened systemically (kanamycin and furosemide) or locally (neomycin).

214 on cotransport blockers, such as SITS, DIDS, furosemide, or bumetanide, when simultaneously added wit

215 albumin every 8 hrs with continuous infusion furosemide, or dual placebo, targeted to diuresis, weigh

216 midodrine plus octreotide, and dopamine plus furosemide over placebo to reduce mortality, and no ORs

217 nation of DMPS with either chlorothiazide or furosemide (P < 0.0001).

218 city of the kidney to secrete anionic drugs (furosemide) paralleled by an approximate 80% decrease in

219 Acute papillectomy or furosemide perfusion was performed to interrupt distal t

220 Furosemide pharmacokinetics were similar for all treatme

221 nd hourly urinary output were used to assess furosemide pharmacokinetics/pharmacodynamics parameters.

222 ed with furosemide plus the high CAP dose or furosemide plus Losartan.

223 de (22 mg/100 g body wt per d) (group 2), or furosemide plus spironolactone (22 and 20 mg/100 g body

224 versus 54 +/- 12 mg for furosemide alone and furosemide plus sulfisoxazole, respectively.

225 d not elaborate Fos in animals injected with furosemide plus the high CAP dose or furosemide plus Los

226 as the other (F+T) received the same dose of furosemide plus TRV120027 (0.3 and 1.5 microg/kg per min

227 inflammation and robust STK-R2* responses to furosemide (possibly reflecting avid tubular oxygen cons

228 Patients with furosemide presented with lower SUV and radioactivity co

229 amiloride-blocked, and amiloride-blocked and furosemide-pretreated), PGE(2) caused relatively small (

230 Furosemide prevented all of these events.

231 The chloride channel inhibitor furosemide prevented intracellular alkalinization, Bax t

232 111, 24%) than in those who did not receive furosemide prior to imaging (79 of 178, 44%, P = .001).

233 se, 178 patients did not receive intravenous furosemide prior to imaging and 111 did.

234 ompared between patients who did not receive furosemide prior to imaging and those who did by using t

235 The Na/K/2Cl transport blocker furosemide produced cell shrinkage in isotonic solution

236 Interestingly, physical mixture containing furosemide, PVP K12 and SDS produced a similar level of

237 ine output correlated with cortical ADC with furosemide (r = 0.7, P = .034) and with medullary lambda

238 Amiloride or furosemide reduced BP in CD ET-1 KO mice on a normal or

239 given at 0, 24, and 48 h, with a fixed-dose furosemide regimen as background therapy.

240 the addition of tolvaptan to a standardized furosemide regimen did not improve the number of respond

241 : (1) Continuation of RSG (RSG-C), (2) RSG + furosemide (RSG+FRUS), (3) RSG + hydrochlorothiazide (RS

242 uded that with either staurosporine or TNF a furosemide-sensitive change in pH(i) is linked to Bax tr

243 d perfusion of cultured cells indicated that furosemide-sensitive Cl- fluxes were located on the baso

244 effect correlates with the existing level of furosemide-sensitive K+-Cl- transport activity in the po

245 The furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter (NK

246 The furosemide-sensitive Na(+)-K(+)-2Cl(-)-cotransporter (NK

247 he Na-K-2Cl-cotransporter NKCC2, and greater furosemide-sensitive Na+ reabsorption in association wit

248 m SPAK/OSR1 Ste20-type kinases, regulate the furosemide-sensitive NKCC2 and the thiazide-sensitive NC

249 The furosemide-sensitive potassium-chloride cotransporter (K

250 allied to in situ immunogold-EM analysis and furosemide-sensitive tonic current estimates revealed th

251 Furosemide shortened the time to left ventricular dysfun

252 repared food), and four weeks of ALDO/salt + furosemide + spironolactone (200 mg/kg/day in divided do

253 In early AKI, urine output after a furosemide stress test (FST), which involves intravenous

254 chaelian kinetics for inhibition of PESAC by furosemide, suggesting a 1:1 stoichiometry for their int

255 In mice, both chlorthiazide and furosemide suppressed the occurrence of maximal electros

256 even with dosing as high as 1,500 mg/kg for furosemide; TD50 was 549 mg/kg.

257 lpha][1,4]benzodiazepine-3 -carboxylate) and furosemide than those recorded from control DGCs.

258 eteral widths were significantly higher with furosemide than with saline for the middle (P </= .04) a

259 For ibuprofen-clarithromycin-furosemide, the elimination profiles were similar irresp

260 Albumin and furosemide therapy improves fluid balance, oxygenation,

261 The addition of albumin to furosemide therapy in hypoproteinemic patients with acut

262 ts were depleted of sodium with the diuretic furosemide three times (3F), one time (2V1F) or sham dep

263 tice has changed from F-15 administration of furosemide to an F + 0 protocol.

264 Intravenous administration of furosemide to pigs subjected to 1 hour of ileal ischemia

265 An early study using furosemide to reversibly reduce EP showed that distortio

266 peritoneal (IP) and intravenous injection of furosemide to reversibly reduce EP.

267 Application of the KCC2 blocker, furosemide, to control neurons mimicked E(GABA) shifts e

268 % (to 3532 +/- 113 units), compared with the furosemide-treated group (P < 0.005).

269 To answer this question, CCD from furosemide-treated mice were perfused in vitro, and the

270 In the short-survival experiment, the furosemide-treated rats had more Fos-positive cell nucle

271 In contrast, furosemide treatment did not produce more Fos-positive c

272 RVR responses during furosemide treatment, assuming complete inhibition of TG

273 When added to furosemide, TRV120027, a novel beta-arrestin biased angi

274 Among them, bumetanide and furosemide, two blockers of Na(+)/K(+)/Cl(-) cotransport

275 Treatment with a loop diuretic, furosemide, under insulinopenic conditions replicates th

276 t had no effect on either the time course of furosemide urinary excretion or overall amount excreted:

277 When BG9719 was given in addition to furosemide, urine volume additionally increased and ther

278 rum sodium was reduced (133.0 +/- 0.9 mmol/l furosemide vs. 135.7 +/- 0.8 mmol/l placebo; p < 0.05),

279 Forty mg of oral furosemide was administered to 13 RYGB recipients and 14

280 Furosemide was administered to examine the effect of inh

281 ower at 3 h after injection, especially when furosemide was applied.

282 Stimulation of renin by furosemide was not affected by mPGES1 deficiency.

283 CI = 0.31-0.90), and a protective effect for furosemide was suggested (OR = 0.44, CI = 0.1-1.9).

284 target of the loop diuretics bumetanide and furosemide, we asked about their effects on HNS function

285 Forty milligrams of furosemide were administered to adults, whereas 0.5 mg/k

286 Additionally, the pharmacokinetics of furosemide were assessed.

287 Loop diuretics other than furosemide were converted to furosemide equivalent doses

288 amide, dichlorphenamide, chlorthalidone, and furosemide were not effective in vivo.

289 Mean opacification scores achieved with furosemide were significantly higher than those achieved

290 Though sulfamethazine and furosemide were used in this study; this principle and m

291 ortant sulfonamide drugs, sulfamethazine and furosemide, were taken and their binding to their respec

292 Treatment with furosemide, which decreases inner-medullary NaCl, reduce

293 uria was still observed after treatment with furosemide, which disrupts calcium and magnesium absorpt

294 Bumetanide and furosemide, which inhibit Cl- influx through the Na(+)-K

295 nal interstitial ATP concentrations, whereas furosemide, which is known to block TGF responses, reduc

296 MHL in the present study was induced using furosemide, which provides a validated model of age-rela

297 s were equally randomly allocated to receive furosemide with albumin or furosemide with placebo for 7

298 ocated to receive furosemide with albumin or furosemide with placebo for 72 hrs, titrated to fluid lo

299 r secretion, and enhance the inactivation of furosemide within the kidney by glucuronidization.

300 The goal was to determine if furosemide would accelerate the progression of left vent